Tvardi Therapeutics Inc. rebounded from a phase II blowup last fall in idiopathic pulmonary fibrosis (IPF) with oral STAT3 inhibitor TTI-101 by showing that a next-gen phosphate prodrug dubbed TTI-109 kept its potency in phase I without gastrointestinal (GI) troubles.
Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2 amplification, limiting the effectiveness of targeted therapies and contributing to its aggressive clinical behavior. As aberrant activation of STAT3 is a key driver of TNBC growth, strategies aimed at suppressing STAT3 signaling are emerging as a potential treatment approach.
Tvardi Therapeutics Inc. stock lost 83.9% of its value as investors took in poor preliminary results of the phase II study of its lead candidate for idiopathic pulmonary fibrosis (IPF). The company’s shares (NASDAQ:TVRD) closed at $6.69 each on Oct. 13.
Shanghai Yuyao Biotech Ltd. has identified new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer.
Altay Therapeutics Inc. has divulged signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes, inflammatory disorders, muscular dystrophy, neurodegeneration and thyroid disorders.
Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease.
Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of inflammatory diseases.
Vividion Therapeutics Inc. has patented 2-azaspiro[3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of cancer.
Researchers from the Second Affiliated Hospital of Fujian Medical University and Shaoxing People's Hospital presented preclinical data for the signal transducer and activator of transcription 3 (STAT3) inhibitor STX-0119, which has been previously validated in models of cancer.
Signal transducer and activator of transcription 3 (STAT3) plays a key role in cell proliferation observed in colorectal cancer (CRC), where up-regulation of STAT3 accelerates tumorigenesis and promotes metastasis.
